Nordic Healthcare outperforms, CS Medica skyrocketing ahead of German IPO, Goldman Sachs new Genmab price target

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.

Last week the Nordic healthcare stocks rose 0.6%, while the Danish healthcare stocks rose 8%. CS Medica is evaluating a potential spin-off of CANNORDIC, Goldman Sachs increased its price target of Genmab, and Pila Pharma completed a directed share issue as well as an agreement with Lindus Health. The Danish healthcare stocks have on average increased 46% year-to-date.

11 of the 22 Danish healthcare companies had a positive share price development the past week and 10 companies have had a positive share price performance year-to-date. Gubra is the best-performing Danish healthcare stock year-to-date with a 415% return and CS Medica was the best Nordic healthcare investment last week. 5 Danish healthcare stocks with +100% YTD return.

Danish company news

Acarix

No news the past week

Ascendis Pharma

No news the past week

Biosergen

No news the past week

Cessatech

Grant of incentive warrants to Employees, CEO and the Board of Directors (Link)

CS Medica

CS MEDICA A/S Evaluates Pre-IPO Share Distribution for CANNORDIC Stock Spin-off (Link)

CS MEDICA Receives “Intention To Grant” for European Patent Application Concerning CANNASEN® Psoriasis Gel, Reinforcing Leadership in CBD-infused Dermatological Innovations (Link)

Curasight

No news the past week

DanCann Pharma

No news the past week

Evaxion Biotech

No news the past week

ExpreS2ion

No news the past week

Fluoguide

No news the past week

Genmab

Goldman Sachs increased its target price from DKK 2242 to DKK 2378

Gubra

No news the past week

Initiator Pharma

No news the past week

IO Biotech

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024 (Link)

Pila Pharma

Pila Pharma’s board of directors announces completion of a fully subscribed directed issue of approximately SEK 10 million (Link)

Pila Pharma inks agreement with Lindus Health about next clinical trial with safety and obesity readouts (Link)

Saniona

No news the past week

Scandion Oncology

No news the past week

SynAct Pharma

No news the past week

ViroGates

No news the past week

Zealand Pharma

No news the past week

Y-mAbs Therapeutics

No news the past week

2cureX

No news the past week

Share price development – Danish stocks

On average, the Danish biotech and healthcare stocks delivered a very strong share price performance the past week with an 8% increase compared to the 0.6% for the KPHC index. CS Medica became the by far best-performing stock with a 158% increase. The company is currently evaluating an IPO share distribution of subsidiary CANNORDIC along with other patent news. However, the stock rose significantly prior to the news of the spin-off and patent news. Genmab rose 4% following an increased price target from Goldman Sachs, and Pila Pharma completed a SEK 10 million directed share issue and signed an agreement with Lindus Health about its next clinical trial with safety and obesity readouts.

The best stock year-to-date is Gubra followed by Pila Pharma with 415% and 262% increases after the first 6 months of trading. CS Medica, Zealand Pharma, and Acarix have also made a +138-218% return year-to-date. Overall the Danish biotech and healthcare stocks are in positive territory this year with a year-to-date return of 46%. In other words, it has had a stellar performance.

Overview of share price development the past week, year-to-date, and the last twelve months

Nordic Biotech & Healthcare Developments

In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) rose 0.6% to 70.91. The index has had a strong performance since the end of April and it has now surpassed the KPNGX index. In the past 12 months, the KPHC index has significantly underperformed relative to large caps, while the venture/small cap Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC index’s downward trajectory down around 5-8%.

The index development for the KPHC index the past year

The KPHC index includes all Nordic healthcare stocks. This means both Novo Nordisk and Genmab as well as Curasight.

158-34% in weekly return for the Nordic healthcare stocks

CS Medica (158%) is a Danish medical device company, dedicated to pharmaceutical research, development, manufacturing, and global commercialization. The company blends science and nature to improve patients’ lives with cannabinoid therapies for pain relief, and to manage autoimmune and stress-related symptoms. Globally, CS Medica offers CBD treatments over-the-counter (OTC), including patented medical products, MHRA, and MDR-registered items, under the CANNASEN® brand or with private labeling.

Arcede Pharma (94%) is a pharmaceutical company. The company conducts research and development in the field of chronic obstructive pulmonary disease, also abbreviated as COPD, and severe asthma. The company’s product portfolio includes drugs intended for the treatment and relief of the above conditions. Most of its activities are in the Nordic market.

Saniona (34%) is a pharmaceutical company. The company conducts research and development in the field of chronic obstructive pulmonary disease, also abbreviated as COPD, and severe asthma. The company’s product portfolio includes drugs intended for the treatment and relief of the above conditions. Most of its activities are in the Nordic market.

Sources: Refinitiv Eikon, Cision, Nordnet & company websites.

Disclaimer

Curasight Investeringscase

Ønsker du at modtage et af vores nyhedsbreve? Udfyld venligst formularen nedenunder.

  • Investeringscases – Nyhedsbreve med top aktuelle investeringscases fra de nordiske vækstbørser og life science sektoren, og ugentlige markedsopdateringer.
  • Børsnoteringer – Opdateringer på nye og igangværende børsnoteringer i Skandinavien samt resultaterne af dem. (Nyhedsbrev fra Nyemission.dk)   
  • Nyheder – Nyheder fra og om Kapital Partner, herunder indsigt om kapitalmarkederne og børsnoteringer samt invitation til investormøder og- arrangementer.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*Hvis du ønsker information om vores kommende investeringsforening med fokus på de nordiske vækstbørser, herunder mulighed for at investere, så tilmeld dig nyhedsbrevet Nyheder.




Investornetværk:

Ønsker du at være en del af Kapital Partners investornetværk, hvor du får adgang til investeringer i selskaber og emissioner, samt indbydelse til investorrettede arrangementer
udfyld venligst formularen her.

Se Casen her

Curasight Investeringscase

Seneste om Curasight

Del indlægget på sociale media eller på email. 

LinkedIn
Facebook
Twitter
Email